Medicines Australia announces Interim CEO
The Board of Medicines Australia, the peak body representing the innovative medicines industry has today announced the appointment of Elizabeth de Somer, as the Interim CEO of Medicines Australia (MA).
Ms de Somer will commence in the role effective Tuesday, 3 April, following the resignation of Milton Catelin, who is returning to the UK.
Medicines Australia Chair Mr Wes Cook, congratulated Ms de Somer on her appointment as Interim CEO.
“Ms de Somer takes on this role with the full support of the MA Board and senior management team,” said Mr Cook.
“I am confident she will provide continuity, stability and strong leadership for both MA and our stakeholders until a permanent appointment is made,” he said.
“Ms de Somer is the current Director Policy & Research within the secretariat and has had a long and successful career within Medicines Australia, having worked within the organisation since 2007. Ms de Somer is highly respected both inside and outside the medicines industry due to ongoing contributions.”
“Medicines Australia is incredibly well positioned to contribute to the development of good health policy in Australia.”
“I’d also like to thank Milton Catelin, who has been in the role since October 2016. Milton has done a tremendous job working with the Board, the secretariat and our members to continue building on strong and meaningful partnerships with our stakeholders,” said Mr Cook.
The MA Board Nominations Sub-Committee has appointed Brooker Consulting to run the recruitment process for a permanent CEO.
More information: Natalie Wimmer – Communications Manager, Medicines Australia
Ph: 0450 728 660